S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.48 (-0.26%)
AAPL   114.20 (-0.66%)
MSFT   207.26 (-1.04%)
FB   261.90 (+1.98%)
GOOGL   1,467.80 (+0.63%)
AMZN   3,149.79 (-0.76%)
TSLA   419.20 (-0.47%)
NVDA   529.40 (+1.53%)
BABA   276.94 (+0.34%)
CGC   14.50 (+2.04%)
GE   6.10 (-1.61%)
MU   51.16 (+2.90%)
AMD   81.80 (+2.92%)
T   28.30 (-0.28%)
F   6.59 (-1.49%)
ACB   4.67 (-2.30%)
GILD   62.09 (-1.21%)
NFLX   493.81 (+0.64%)
DIS   125.30 (-0.55%)
BA   163.90 (-1.31%)
BAC   23.78 (-1.29%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.48 (-0.26%)
AAPL   114.20 (-0.66%)
MSFT   207.26 (-1.04%)
FB   261.90 (+1.98%)
GOOGL   1,467.80 (+0.63%)
AMZN   3,149.79 (-0.76%)
TSLA   419.20 (-0.47%)
NVDA   529.40 (+1.53%)
BABA   276.94 (+0.34%)
CGC   14.50 (+2.04%)
GE   6.10 (-1.61%)
MU   51.16 (+2.90%)
AMD   81.80 (+2.92%)
T   28.30 (-0.28%)
F   6.59 (-1.49%)
ACB   4.67 (-2.30%)
GILD   62.09 (-1.21%)
NFLX   493.81 (+0.64%)
DIS   125.30 (-0.55%)
BA   163.90 (-1.31%)
BAC   23.78 (-1.29%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.48 (-0.26%)
AAPL   114.20 (-0.66%)
MSFT   207.26 (-1.04%)
FB   261.90 (+1.98%)
GOOGL   1,467.80 (+0.63%)
AMZN   3,149.79 (-0.76%)
TSLA   419.20 (-0.47%)
NVDA   529.40 (+1.53%)
BABA   276.94 (+0.34%)
CGC   14.50 (+2.04%)
GE   6.10 (-1.61%)
MU   51.16 (+2.90%)
AMD   81.80 (+2.92%)
T   28.30 (-0.28%)
F   6.59 (-1.49%)
ACB   4.67 (-2.30%)
GILD   62.09 (-1.21%)
NFLX   493.81 (+0.64%)
DIS   125.30 (-0.55%)
BA   163.90 (-1.31%)
BAC   23.78 (-1.29%)
S&P 500   3,335.47 (-0.48%)
DOW   27,452.66 (-0.48%)
QQQ   276.48 (-0.26%)
AAPL   114.20 (-0.66%)
MSFT   207.26 (-1.04%)
FB   261.90 (+1.98%)
GOOGL   1,467.80 (+0.63%)
AMZN   3,149.79 (-0.76%)
TSLA   419.20 (-0.47%)
NVDA   529.40 (+1.53%)
BABA   276.94 (+0.34%)
CGC   14.50 (+2.04%)
GE   6.10 (-1.61%)
MU   51.16 (+2.90%)
AMD   81.80 (+2.92%)
T   28.30 (-0.28%)
F   6.59 (-1.49%)
ACB   4.67 (-2.30%)
GILD   62.09 (-1.21%)
NFLX   493.81 (+0.64%)
DIS   125.30 (-0.55%)
BA   163.90 (-1.31%)
BAC   23.78 (-1.29%)
Log in
NASDAQ:EOLS

Evolus Stock Forecast, Price & News

$3.81
+0.07 (+1.87 %)
(As of 09/29/2020 03:59 PM ET)
Add
Compare
Today's Range
$3.67
Now: $3.81
$3.82
50-Day Range
$3.37
MA: $3.72
$4.04
52-Week Range
$3.00
Now: $3.81
$17.68
Volume17,274 shs
Average Volume794,925 shs
Market Capitalization$128.58 million
P/E RatioN/A
Dividend YieldN/A
Beta2.83
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California. Evolus, Inc. is a subsidiary of ALPHAEON Corporation.
Read More
Evolus logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EOLS
CUSIPN/A
Phone949-284-4555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.92 million
Book Value$2.38 per share

Profitability

Net Income$-90,030,000.00
Net Margins-161.74%

Miscellaneous

Employees70
Market Cap$128.58 million
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$3.81
+0.07 (+1.87 %)
(As of 09/29/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EOLS News and Ratings via Email

Sign-up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Evolus (NASDAQ:EOLS) Frequently Asked Questions

How has Evolus' stock price been impacted by Coronavirus?

Evolus' stock was trading at $5.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EOLS stock has decreased by 35.5% and is now trading at $3.81.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Evolus?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Evolus
.

When is Evolus' next earnings date?

Evolus is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Evolus
.

How were Evolus' earnings last quarter?

Evolus Inc (NASDAQ:EOLS) posted its earnings results on Monday, August, 10th. The company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.84) by $0.21. The firm earned $7.81 million during the quarter, compared to analyst estimates of $2.48 million. Evolus had a negative return on equity of 162.50% and a negative net margin of 161.74%.
View Evolus' earnings history
.

What price target have analysts set for EOLS?

7 analysts have issued 1 year price targets for Evolus' shares. Their forecasts range from $4.00 to $25.00. On average, they expect Evolus' share price to reach $9.71 in the next year. This suggests a possible upside of 155.0% from the stock's current price.
View analysts' price targets for Evolus
.

Who are some of Evolus' key competitors?

What other stocks do shareholders of Evolus own?

Who are Evolus' key executives?

Evolus' management team includes the following people:
  • Mr. David Moatazedi, Pres, CEO & Director (Age 41)
  • Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 60)
  • Mr. Michael Mazen Jafar, Chief Marketing Officer (Age 38)
  • Mr. Alejandro Sabad, VP of Operations
  • Mr. Ashwin K. Agarwal, VP of Fin., Investor Relations & Treasury

When did Evolus IPO?

(EOLS) raised $65 million in an initial public offering (IPO) on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

How do I buy shares of Evolus?

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $3.81.

How big of a company is Evolus?

Evolus has a market capitalization of $128.58 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Evolus employs 70 workers across the globe.

What is Evolus' official website?

The official website for Evolus is www.evolus.com.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.